Abstracts tagged "Biologic agents"

Abstract Number: 876 • 2016 ACR/ARHP Annual Meeting
Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis
Richard Conway¹, Lorraine O'Neill², Phil Gallagher³, Eileen O'Flynn⁴, Geraldine M. McCarthy⁵, Conor Murphy⁶, Douglas J. Veale⁷, Ursula Fearon⁸ and Eamonn S. Molloy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁵Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁶Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁷Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁸Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁹Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids with attendant significant adverse events. There is a critical need for alternative therapies. Interleukins…
Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
J. Antonio Avina-Zubieta¹, Andrew Chow², Philip Baer³, John Kelsall⁴, Proton Rahman⁵, Jacqueline Stewart⁶, Boulos Haraoui⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Francois Nantel¹¹, Karina Maslova¹², Cathy Tkaczyk¹³, Brendan Osborne¹³ and Allen J Lehman¹², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Independent Rheumatology Practice, Scarborough, ON, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Montreal, Montreal, QC, Canada, ⁸Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 426 • 2015 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen⁴, Melissa L. Mannion⁵, Kenneth G. Saag⁴, Jie Zhang⁶ and Jeffrey R. Curtis⁴, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are highly effective for the treatment of juvenile idiopathic arthritis (JIA) but have the potential risk of increased serious infections. Using observational…
Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting
Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
T. W. J. Huizinga¹, Anastas Batalov², Rumen Stoilov³, Eric Lloyd⁴, Thomas Wagner⁵, Didier Saurigny⁶, Bernard Souberbielle⁶ and Ehsanollah Esfandiari⁶, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²UMHAT Kaspela, Plovdiv, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Takeda Pharmaceuticals, Deerfield, IL, ⁵Takeda Pharmaceuticals, Zurich, Switzerland, ⁶Takeda Pharmaceuticals, London, United Kingdom
Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…
Abstract Number: 1630 • 2015 ACR/ARHP Annual Meeting
Progressive Destruction of Large Joints in Patients with Rheumatoid Arthritis Treated with Biologic Agents
Arata Nakajima¹, Masato Sonobe² and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Many clinical trials have revealed that biologic agents inhibit destruction of small joints, however, there have been a few reports demonstrating their inhibitory effects…
Abstract Number: 2555 • 2015 ACR/ARHP Annual Meeting
14-3-3η As a Novel RA Drug Target: Anti-14-3-3η Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice
Abedelnasser Abulrob¹, Mario Mercier¹, Slavisa Corluka¹, Roger MacKenzie¹, Shalini Raphael¹, Sara Michienzi², Jane Savill², Yuan Gui², Walter Maksymowych³ and Anthony Marotta², ¹National Research Council of Canada, Ottawa, ON, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: As an extracellular ligand, 14-3-3η potently and concentration-dependently upregulates the expression of multiple factors including TNFα, IL-6, and RANKL and its clinical detection is…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 437 • 2015 ACR/ARHP Annual Meeting
Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Tanja Schjødt Jørgensen¹, Carl Turesson², Meliha C. Kapetanovic³, Martin Englund^4,5, Aleksandra Turkiewicz⁴, Robin Christensen¹, Henning Bliddal¹, Pierre Geborek³ and Lars Erik Kristensen¹, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: About 30% of patients receiving biologic therapy do not have concomitant conventional synthetic DMARDs (csDMARDs). Little is known about the role of different mode…
Abstract Number: 970 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study
Roy Fleischmann¹, Geraldo Castelar-Pinheiro², Jan Brzezicki³, Pawel Hrycaj⁴, Yong Lin⁵, Janet van Adelsberg⁶, Neil Graham⁷, Hubert van Hoogstraten⁵, Deborah Bauer⁵ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ³Centrum Kliniczno-Badawcze, Elblag, Poland, ⁴Poznan University of Medical Sciences, Poznan, Poland, ⁵Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. The phase 3 MOBILITY study (NCT01061736) evaluated the efficacy and safety…
Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting
Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Zulema Rosales^1,2, Leticia Leon¹, Alejandro Gomez-Gomez², Lucía Arietti², Esperanza Pato Cour², José Luis Fernández Rueda¹, Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…
Abstract Number: 2728 • 2015 ACR/ARHP Annual Meeting
Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting
E Alemao¹, S Joo², M Frits³, C Iannaccone³, N Shadick³ and Michael Weinblatt³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic (b)DMARDs have advanced the standard of care in RA, reducing unmet needs and increasing remission rates. Abatacept (ABA) is approved for the management…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].